Relevance: Investigators conducted a post hoc secondary analysis of 4 randomized clinical trials that enrolled 2682 patients in Europe, North America, Russia, and Turkey. The participants received placebo or a monthly subcutaneous injection of erenumab during the 12- to 24-week treatment phases and extension phases that ranged from 28 weeks to 5...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrI would not expect different results.
Post-marketing safety surveillance of erenumab: new insight from Eudravigilance
Source : https://www.tandfonline.com/doi/abs/10.1080/14740338.2022.2049231?journalCode=ieds20
Abstract We aimed at evaluating adverse drug reactions during the post-marketing phase with erenumab as the suspected/interacting drug in Eudravigilance, with the final goal of investigating the consistency of the...
Conclusions: Adverse events reports were mostly reported as non-serious. The co-analysis of multiple spontaneous reported databases unveiled undetected disproportionality signals for erenumab in individual databases. Future studies should be conducted to confirm the associations and potential clinical implications.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is great to have real life data.
Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-022-02591-8
Objective To assess the nocioceptive input of habitual nocturnal jaw clenching that acts as a contributing factor in migraine pathogenesis. Background Habitual nocturnal jaw clenching has been implicated as a...
Conclusion: The improvement in HIT-6 scores produced by the NTI device, suggests that patients with Chronic Migraine may have intense nocturnal jaw clenching as a contributing factor to their headache related disability. An NTI device is one method of assessing whether jaw-clenching is a contributing factor to ongoing migraine.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrIt is so important to screen for chewing or grinding in patients.
Successful treatment of primary headache associated with sexual activity using erenumab: Case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35166159/
1 Faculty of Medicine, 54694Vilnius University, Vilnius University, Vilnius, Lithuania. 2 Centre of Neurology, 54694Vilnius University, Vilnius University, Vilnius, Lithuania. 3 Centre of Neurology, Kardiolitos klinikos, Vilnius, Lithuania. Free article...
Conclusion:The efficacy of erenumab in our case presumes that CGRP might also be an important mediator in facilitating primary headache associated with sexual activity.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrAll of these may be variants of migriane.
The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35162776/
doi: 10.3390/ijerph19031753. 1 Health and Social Research Center, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain. 2 Pharmacy Service, Hospital Virgen de la Luz, 16002 Cuenca, Spain. 3 Universidad Politécnica y...
Conclusions: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrGlad to have wider studies.
-
Migraine Connect3yrKey Points • Source: International Journal of Environmental Research and Public Health • Conclusions/Relevance: “This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP Show More